Supplemental Figure 1



Supplemental Figure S1: Epoxygenase inhibition increase macrophage lipid uptake. SKF525A treatment (10μM; 72h) increases the uptake of DiL-acetylated LDL which is inhibited if co-treated with the selective PPARα ligand GW7647 (100nM). Cells were initially pre-treated with PMA (5nM) for 24h. Left panels show representative micrographs (x400) of ac-LDL uptake, figure shows densometric analysis (Image J) of ac-LDL uptake represented as mean ± SEM of n=4 experiments.

Supplemental Figure 2



Supplemental Figure S2: (A & B) shows COX-2 mRNA (C) and TNFα mRNA (D) relative to β-actin in THP-1 cells treated with vehicle (Cont), or treated with SKF525A (10μM), IL-4 (20ng/ml or IL-4 with SKF525A for 7h. Data represents mean ± SEM of n=4 experiments. * indicates $p<0.05$; one way ANOVA compared to control. **(C)** Intracellular cAMP levels (pg/ml) are unchanged in THP-1 cells treated with vehicle control (Cont) or SKF525A (10μM) for 7h. **(D)** Shows the comparison of inhibition of basal TNFα release from THP-1 cells treated with 1μM of 11,12-EET or 9,10-EPOME. Data represents mean ± SEM of n=3 experiments.